Liver cancer incidence and mortality in China: Temporal trends and projections to 2030

Rongshou Zheng, Chunfeng Qu, Siwei Zhang, Hongmei Zeng, Kexin Sun, Xiuying Gu, Changfa Xia, Zhixun Yang, He Li, Wenqiang Wei, Wanqing Chen, Jie He, Rongshou Zheng, Chunfeng Qu, Siwei Zhang, Hongmei Zeng, Kexin Sun, Xiuying Gu, Changfa Xia, Zhixun Yang, He Li, Wenqiang Wei, Wanqing Chen, Jie He

Abstract

Objective: Liver cancer is one of the most common cancers and major cause of cancer deaths in China, which accounts for over 50% of new cases and deaths worldwide. The systematic liver cancer statistics including of projection through 2030 could provide valuable information for prevention and control strategies in China, and experience for other countries.

Methods: The burden of liver cancer in China in 2014 was estimated using 339 cancer registries' data selected from Chinese National Cancer Center (NCC). Incident cases of 22 cancer registries were applied for temporal trends from 2000 to 2014. The burden of liver cancer through 2030 was projected using age-period-cohort model.

Results: About 364,800 new cases of liver cancer (268,900 males and 95,900 females) occurred in China, and about 318,800 liver cancer deaths (233,500 males and 85,300 females) in 2014. Western regions of China had the highest incidence and mortality rates. Incidence and mortality rates decreased by about 2.3% and 2.6% per year during the period of 2000-2014, respectively, and would decrease by more than 44% between 2014 and 2030 in China. The young generation, particularly for those aged under 40 years, showed a faster down trend.

Conclusions: Based on the analysis, incidence and mortality rates of liver cancer are expected to decrease through 2030, but the burden of liver cancer is still serious in China, especially in rural and western areas. Most cases of liver cancer in China can be prevented through vaccination and more prevention efforts should be focused on high risk groups.

Keywords: China; Liver cancer burden; cancer registry; prediction; temporal trends.

Figures

S1
S1
Distribution of 339 selected cancer registries in China.
S2
S2
Liver cancer incidence and mortality rates with different birth cohorts by age groups in China. (A) Male incidence; (B) Female incidence; (C) Urban incidence; (D) Rural incidence; (E) Male mortality; (F) Female mortality; (G) Urban mortality; (H) Rural mortality.
1
1
Trends for age-specific incidence and mortality rates during 2000−2014 and predicted from 2015 to 2030, and the total prevented liver cancer cases and avoided deaths between the top rate in 2014 and 2030 in China. (A) Male incidence; (B) Female incidence; (C) Male mortality; (D) Female mortality; (E) Male cases; (F) Female cases; (G) Male deaths; (H) Female deaths. Right panel: black line represents predicted cancer cases or deaths from 2014 to 2030; red line represents estimated numbers of total liver cancer cases or deaths by applying 2014 age-specific incidence or mortality rate.
2
2
Contribution of ever-smoking, hepatitis B, hepatitis C, alcohol, excess body weight and other causes on liver cancer incidence both sexes and by areas in China.

References

    1. Bray F, Ferlay J, Soerjomataram I, et al Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. doi: 10.3322/caac.21492. [Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424]
    1. Sia D, Villanueva A, Friedman SL, et al Liver cancer cell of origin, molecular class, and effects on patient prognosis. Gastroenterology. 2017;152:745–61. doi: 10.1053/j.gastro.2016.11.048. [Sia D, Villanueva A, Friedman SL, et al. Liver cancer cell of origin, molecular class, and effects on patient prognosis. Gastroenterology 2017;152:745-61]
    1. Massarweh NN, El-Serag HB Epidemiology of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Cancer Control. 2017;24:1073274817729245. doi: 10.1177/1073274817729245. [Massarweh NN, El-Serag HB. Epidemiology of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Cancer Control 2017;24:1073274817729245]
    1. de Martel C, Maucort-Boulch D, Plummer M, et al World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma. Hepatology. 2015;62:1190–200. doi: 10.1002/hep.27969. [de Martel C, Maucort-Boulch D, Plummer M, et al. World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma. Hepatology 2015;62:1190-200]
    1. Poon D, Anderson BO, Chen LT, et al Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol. 2009;10:1111–8. doi: 10.1016/S1470-2045(09)70241-4. [Poon D, Anderson BO, Chen LT, et al. Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 2009;10:1111-8]
    1. Islami F, Chen W, Yu XQ, et al Cancer deaths and cases attributable to lifestyle factors and infections in China, 2013. Ann Oncol. 2017;28:2567–74. doi: 10.1093/annonc/mdx342. [Islami F, Chen W, Yu XQ, et al. Cancer deaths and cases attributable to lifestyle factors and infections in China, 2013. Ann Oncol 2017;28:2567-74]
    1. Sun Z, Chen T, Thorgeirsson SS, et al Dramatic reduction of liver cancer incidence in young adults: 28 year follow-up of etiological interventions in an endemic area of China. Carcinogenesis. 2013;34:1800–5. doi: 10.1093/carcin/bgt007. [Sun Z, Chen T, Thorgeirsson SS, et al. Dramatic reduction of liver cancer incidence in young adults: 28 year follow-up of etiological interventions in an endemic area of China. Carcinogenesis 2013;34:1800-5]
    1. Papatheodoridis GV, Idilman R, Dalekos GN, et al The risk of hepatocellular carcinoma decreasing after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. Hepatology. 2017;66:1444–53. doi: 10.1002/hep.29320. [Papatheodoridis GV, Idilman R, Dalekos GN, et al. The risk of hepatocellular carcinoma decreasing after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. Hepatology 2017;66:1444-53]
    1. Wu CY, Lin JT, Ho HJ, et al Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study. Gastroenterology. 2014;147:143–51. e5. doi: 10.1053/j.gastro.2014.03.048. [Wu CY, Lin JT, Ho HJ, et al. Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study. Gastroenterology 2014;147:143-51. e5]
    1. Islami F, Miller KD, Siegel RL, et al Disparities in liver cancer occurrence in the United States by race/ethnicity and state. CA Cancer J Clin. 2017;67:273–89. doi: 10.3322/caac.21402. [Islami F, Miller KD, Siegel RL, et al. Disparities in liver cancer occurrence in the United States by race/ethnicity and state. CA Cancer J Clin 2017;67:273-89]
    1. Global Burden of Disease Liver Cancer Collaboration The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015. JAMA Oncol. 2017;3:1683–91. doi: 10.1001/jamaoncol.2017.3055. [Global Burden of Disease Liver Cancer Collaboration. The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015. JAMA Oncol 2017;3:1683-91]
    1. White DL, Thrift AP, Kanwal F, et al Incidence of hepatocellular carcinoma in all 50 United States, from 2000 through 2012. Gastroenterology. 2017;152:812–20. e5. doi: 10.1053/j.gastro.2016.11.020. [White DL, Thrift AP, Kanwal F, et al. Incidence of hepatocellular carcinoma in all 50 United States, from 2000 through 2012. Gastroenterology 2017;152:812-20. e5]
    1. Wang M, Wang Y, Feng X, et al Contribution of hepatitis B virus and hepatitis C virus to liver cancer in China north areas: Experience from Chinese National Cancer Center. Int J Infect Dis. 2017;65:15–21. doi: 10.1016/j.ijid.2017.09.003. [Wang M, Wang Y, Feng X, et al. Contribution of hepatitis B virus and hepatitis C virus to liver cancer in China north areas: Experience from Chinese National Cancer Center. Int J Infect Dis 2017;65:15-21]

    1. Wu M, Shen F. Liver Cancer. 3rd ed. Beijing: Peking University Medical Press, 2010:327.

    1. Chiang CJ, Yang YW, You SL, et al Thirty-year outcomes of the national hepatitis B immunization program in Taiwan. JAMA. 2013;310:974–6. doi: 10.1001/jama.2013.276701. [Chiang CJ, Yang YW, You SL, et al. Thirty-year outcomes of the national hepatitis B immunization program in Taiwan. JAMA 2013;310:974-6]
    1. Qu C, Chen T, Fan C, et al Efficacy of neonatal HBV vaccination on liver cancer and other liver diseases over 30-year follow-up of the Qidong hepatitis B intervention study: a cluster randomized controlled trial. PLoS Med. 2014;11:e1001774. doi: 10.1371/journal.pmed.1001774. [Qu C, Chen T, Fan C, et al. Efficacy of neonatal HBV vaccination on liver cancer and other liver diseases over 30-year follow-up of the Qidong hepatitis B intervention study: a cluster randomized controlled trial. PLoS Med 2014;11:e1001774]
    1. Chen W, Zheng R, Baade PD, et al Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–32. doi: 10.3322/caac.21338. [Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin 2016;66:115-32]
    1. Qu C, Duan Z, Chen K, et al Reducing liver cancer risk beginning at birth: experiences of preventing chronic hepatitis B virus infection in China. Hepatoma Res. 2017;3:228–40. doi: 10.20517/2394-5079.2017.41. [Qu C, Duan Z, Chen K, et al. Reducing liver cancer risk beginning at birth: experiences of preventing chronic hepatitis B virus infection in China. Hepatoma Res 2017;3:228-40]
    1. Torre LA, Bray F, Siegel RL, et al Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108. doi: 10.3322/caac.21262. [Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108]

    1. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. International Agency for Research on Cancer, 2013. Available online: http://globocan.iarc.fr

    1. Allemani C, Weir HK, Carreira H, et al Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2) Lancet. 2015;385:977–1010. doi: 10.1016/S0140-6736(14)62038-9. [Allemani C, Weir HK, Carreira H, et al. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 2015;385:977-1010]
    1. Bray F, Guilloux A, Sankila R, et al Practical implications of imposing a new world standard population. Cancer Causes Control. 2002;13:175–82. doi: 10.1023/A:1014344519276. [Bray F, Guilloux A, Sankila R, et al. Practical implications of imposing a new world standard population. Cancer Causes Control 2002;13:175-82]
    1. Malvezzi M, Carioli G, Bertuccio P, et al European cancer mortality predictions for the year 2017, with focus on lung cancer. Ann Oncol. 2017;28:1117–23. doi: 10.1093/annonc/mdx033. [Malvezzi M, Carioli G, Bertuccio P, et al. European cancer mortality predictions for the year 2017, with focus on lung cancer. Ann Oncol 2017;28:1117-23]
    1. Møller B, Fekjaer H, Hakulinen T, et al Prediction of cancer incidence in the Nordic countries up to the year 2020. Eur J Cancer Prev. 2002;11 Suppl 1:S1–96. [Møller B, Fekjaer H, Hakulinen T, et al. Prediction of cancer incidence in the Nordic countries up to the year 2020. Eur J Cancer Prev 2002;11 Suppl 1:S1-96]
    1. Global Burden of Disease Cancer Collaboration The global burden of cancer 2013. JAMA Oncol. 2015;1:505–27. doi: 10.1001/jamaoncol.2015.0735. [Global Burden of Disease Cancer Collaboration. The global burden of cancer 2013. JAMA Oncol 2015;1:505-27]
    1. Chen W, Zheng R, Zhang S, et al Cancer incidence and mortality in China, 2013. Cancer Lett. 2017;401:63–71. doi: 10.1016/j.canlet.2017.04.024. [Chen W, Zheng R, Zhang S, et al. Cancer incidence and mortality in China, 2013. Cancer Lett 2017;401:63-71]
    1. Cai Y, Xue M, Chen W, et al Expenditure of hospital care on cancer in China, from 2011 to 2015. Chin J Cancer Res. 2017;29:253–62. doi: 10.21147/j.issn.1000-9604.2017.03.11. [Cai Y, Xue M, Chen W, et al. Expenditure of hospital care on cancer in China, from 2011 to 2015. Chin J Cancer Res 2017;29:253-62]
    1. Zeng H, Chen W, Zheng R, et al Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries. Lancet Glob Health. 2018;6:e555–e567. doi: 10.1016/S2214-109X(18)30127-X. [Zeng H, Chen W, Zheng R, et al. Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries. Lancet Glob Health 2018;6:e555-e567]
    1. Sun Z, Ming L, Zhu X, et al Prevention and control of hepatitis B in China. J Med Virol. 2002;67:447–50. doi: 10.1002/jmv.10094. [Sun Z, Ming L, Zhu X, et al. Prevention and control of hepatitis B in China. J Med Virol 2002;67:447-50]
    1. Liu J, Zhang S, Wang Q, et al Seroepidemiology of hepatitis B virus infection in 2 million men aged 21-49 years in rural China: a population-based, cross-sectional study. Lancet Infect Dis. 2016;16:80–6. doi: 10.1016/S1473-3099(15)00218-2. [Liu J, Zhang S, Wang Q, et al. Seroepidemiology of hepatitis B virus infection in 2 million men aged 21-49 years in rural China: a population-based, cross-sectional study. Lancet Infect Dis 2016;16:80-6]
    1. Chen JG, Egner PA, Ng D, et al Reduced aflatoxin exposure presages decline in liver cancer mortality in an endemic region of China. Cancer Prev Res (Phila) 2013;6:1038–45. doi: 10.1158/1940-6207.CAPR-13-0168. [Chen JG, Egner PA, Ng D, et al. Reduced aflatoxin exposure presages decline in liver cancer mortality in an endemic region of China. Cancer Prev Res (Phila) 2013;6:1038-45]
    1. Zhang W, Shu XO, Li H, et al Vitamin intake and liver cancer risk: a report from two cohort studies in China. J Natl Cancer Inst. 2012;104:1173–81. doi: 10.1093/jnci/djs277. [Zhang W, Shu XO, Li H, et al. Vitamin intake and liver cancer risk: a report from two cohort studies in China. J Natl Cancer Inst 2012;104:1173-81]
    1. Kurahashi N, Inoue M, Iwasaki M, et al Vegetable, fruit and antioxidant nutrient consumption and subsequent risk of hepatocellular carcinoma: a prospective cohort study in Japan. Br J Cancer. 2009;100:181–4. doi: 10.1038/sj.bjc.6604843. [Kurahashi N, Inoue M, Iwasaki M, et al. Vegetable, fruit and antioxidant nutrient consumption and subsequent risk of hepatocellular carcinoma: a prospective cohort study in Japan. Br J Cancer 2009;100:181-4]
    1. Wang FS, Fan JG, Zhang Z, et al The global burden of liver disease: the major impact of China. Hepatology. 2014;60:2099–108. doi: 10.1002/hep.27406. [Wang FS, Fan JG, Zhang Z, et al. The global burden of liver disease: the major impact of China. Hepatology 2014;60:2099-108]
    1. Bray F, Møller B Predicting the future burden of cancer. Nat Rev Cancer. 2006;6:63–74. doi: 10.1038/nrc1781. [Bray F, Møller B. Predicting the future burden of cancer. Nat Rev Cancer 2006;6:63-74]
    1. Wu J, Yang S, Xu K, et al Patterns and trends of liver cancer incidence rates in Eastern and Southeastern Asian countries (1983-2007) and predictions to 2030. Gastroenterology. 2018;154:1719–28. e5. doi: 10.1053/j.gastro.2018.01.033. [Wu J, Yang S, Xu K, et al. Patterns and trends of liver cancer incidence rates in Eastern and Southeastern Asian countries (1983-2007) and predictions to 2030. Gastroenterology 2018;154:1719-28. e5]

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅